AlliReport.com Provides Latest News About Over-the-Counter Alli, Low-Dose Xenical

Share Article

AlliReport.com, an independent news site published by Medical Week News, Inc., provides the latest news about Alli, trade name for low-dose Xenical. Alli, which is half the strength of prescription Xenical (orlistat), is seeking approval to become the first prescription weight-loss drug to be sold over-the-counter. Medical Week News also publishes the highly rated site, AcompliaReport.com, reporting on the new prescription weight-loss drug, Acomplia (rimonabant).

Medical Week News, Inc., publisher of the highly rated Acomplia Report (http://www.acompliareport.com), announced it has launched a new guide to weight-loss drugs called Alli Report (http://www.allireport.com) to cover latest news about the new over-the-counter version of the prescription weight-loss medication Xenical (orlistat).

“With Alli awaiting U.S. Food and Drug Administration (FDA) approval to be sold without a prescription, we believe a growing number of Americans will soon be searching for independent, objective news and information about the benefits and risks of taking this low-dose version of Xenical,” said Milton R. Benjamin, publisher of Alli Report (http://www.allireport.com).

“We intend to provide all the positive and negative expert opinions on the use of Alli just as our other obesity publication, Acomplia Report (http://www.acompliareport.com), provides all the news about the prescription drug rimonabant as it makes its way through the FDA and European approval processes,” Benjamin added.

The Alli Report (http://www.allireport.com) will be updated daily by Medical Week News, and will keep readers fully informed on the FDA approval process, and when this over-the-counter version of low-dose Xenical will be available to the public.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Milton Benjamin
Visit website